Trimtech Therapeutics, a biotech company pioneering targeted protein degradation (TPD) for neurodegenerative diseases, has raised $31 million (£25 million) in seed funding to propel the development of its next-generation CNS-targeted therapeutics.

The investment was led by Cambridge Innovation Capital (CIC) and SV Health Investors’ Dementia Discovery Fund (DDF), with participation from M Ventures and Pfizer Ventures. Additional backers include Eli Lilly and Company, MP Healthcare Venture Management (MPH), Cambridge Enterprise Ventures, and Start Codon.

Advancing CNS-Penetrant Therapies

Trimtech is harnessing the unique capabilities of TRIM21, an E3 ubiquitin ligase, to develop TRIMTAC™ molecules, a new class of aggregate-selective degraders. These molecules are designed to effectively clear toxic protein aggregates, a major contributor to neurodegenerative diseases like Alzheimer’s and Huntington’s, while leaving functional proteins intact.

Unlike conventional protein degradation approaches, which often struggle to penetrate the central nervous system (CNS) or effectively target misfolded proteins, Trimtech’s precision technology offers a potential breakthrough in addressing these long-standing challenges.

A Strong Foundation of Scientific Expertise

Trimtech was founded through a collaboration between Cambridge Innovation Capital (CIC) and SV Health Investors’ DDF, along with entrepreneur-in-residence Damian Crowther and scientific co-founders Leo James (MRC Laboratory of Molecular Biology) and Will McEwan (UK Dementia Research Institute, University of Cambridge).

To support its next phase of growth, the company has appointed leading industry figures to its Board of Directors:

• Michael Anstey, Partner, Cambridge Innovation Capital
• Laurence Barker, Partner, SV Health Investors
• Hakan Goker, Managing Director, M Ventures
• Jeffrey Moore, President, MP Healthcare Venture Management
• Marie-Claire Peakman, Partner, Pfizer Ventures

Leadership Perspectives

Nicola Thompson, CEO of Trimtech Therapeutics, highlighted the significance of this funding milestone:

“The overwhelming investor support reflects the confidence in our approach to tackling neurodegenerative diseases through targeted protein degradation. With this funding, we are poised to accelerate the development of our TRIMTAC platform and advance novel treatments for patients in desperate need of effective therapies.”

Laurence Barker, Partner at SV Health Investors’ DDF, emphasized the platform’s potential:

“While targeted protein degradation has revolutionized drug discovery, addressing protein aggregation remains a critical challenge. Trimtech’s approach represents a game-changer, offering a new path forward for patients suffering from neurodegenerative conditions.”

Michael Anstey, Partner at Cambridge Innovation Capital, reinforced the company’s impact:

“With millions of people worldwide affected by neurodegenerative diseases, the need for innovative solutions has never been more pressing. Trimtech’s breakthrough technology could redefine how these conditions are treated.”

Looking to the Future

With this funding, Trimtech Therapeutics is set to expand its research efforts, advance its TRIMTAC pipeline, and push the boundaries of neurodegenerative disease treatment.